Mandate

Vinge has advised Oncopeptides in connection with entering into renewed agreements regarding a loan facility of up to EUR 30 million from the European Investment Bank

The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.

Oncopeptides is a biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company´s lead product is approved on several markets for treatment of adult patients with multiple myeloma. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (finance) as well as Dain Hård Nevonen and Linnéa Sellström (capital markets).

Related

Vinge has advised Eleda in connection with the acquisition of Sartor & Drange AS

Vinge, together with Thommessen, advised the infrastructure group Eleda in connection with the acquisition of Sartor & Drange AS, a market-leading civil engineering contractor in the Bergen region. Sartor & Drange AS offers services in areas such as road, water and sewerage and foundation work in Western Norway. Sartor & Drange AS has approximately 200 employees and a turnover of approximately NOK 1,100 million.
June 17, 2024

Vinge has advised Svea Bank AB in connection with the issuance of callable tier 2 capital bonds (T2) of SEK 300 million

Vinge has advised Svea Bank AB in connection with its issuance of SEK 300 million callable tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 6.75%. The issue date is set to 7 June 2024, and the bonds have a maturity of 10.25 years with first permitted redemption date after 5 years. The instruments will be listed on Nasdaq Stockholm.
June 14, 2024

Vinge advises Axcel and XPartners in connection with the acquisition of HTJ

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of HTJ Holding OY and its subsidiary Rakennuttajatoimisto HTJ Oy (”HTJ”).
June 13, 2024